Hudson Bay Capital Management
AKBA icon

Hudson Bay Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Hudson Bay Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-245,000
Closed -$615K – 588
2020
Q3 		$615K Buy
245,000
+45,000
+23% +$395K 0.01% 458
2020
Q2 		$2.72M Buy
200,000
+45,000
+29% +$466K 0.05% 276
2020
Q1 		$1.18M Buy
155,000
+55,000
+55% +$428K 0.03% 308
2019
Q4 		$632K Buy
+100,000
New +$475K 0.01% 336

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Hudson Bay Capital Management's AKBA Position: Q4 2020 in Review

Hudson Bay Capital Management sold out of Akebia Therapeutics (AKBA) in Q4 2020, closing a stake of 245,000 shares — an estimated $615K sold.

Hudson Bay Capital Management first reported a position in AKBA in Q4 2019 and held it in 4 quarters. The position peaked at $2.72M in Q2 2020. 143 funds tracked by Wall St. Rank hold AKBA as of Q4 2020.

  • Hudson Bay Capital Management reported no remaining Akebia Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Hudson Bay Capital Management sold 245,000 Akebia Therapeutics shares in Q4 2020, an estimated $615K.
  • Hudson Bay Capital Management first reported a position in Akebia Therapeutics in Q4 2019 and held it in 4 quarters.
  • Hudson Bay Capital Management's Akebia Therapeutics position peaked at $2.72M in Q2 2020.
  • 143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2020.

Based on Hudson Bay Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.